Circulating tumor necrosis factor (TNF)-α and soluble TNF-α receptors in patients with Guillain-Barre syndrome

Journal of Neuroimmunology

Volumn 68, Issue 1-2, 1996, Pages 95-99

  Creange A ^a   Belec L ^a,b   Clair, B ^c   Raphael J C ^c   Gherardi, R K ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b HÔPITAL BROUSSAIS   (France)

^c RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

Cytokine; Demyelinating neuropathy; Guillain Barre syndrome; Tumor necrosis factor ; Tumor necrosis factor soluble receptor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ARTICLE; AUTOIMMUNITY; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATING NEUROPATHY; DIAGNOSIS; ETIOLOGY; GUILLAIN BARRE SYNDROME; HUMAN; PRIORITY JOURNAL;

EID: 0030219847     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/0165-5728(96)00075-6     Document Type: Article

References (38)

1. Aderka D., Engelmann H., Hornik V., Skornick Y., Levo Y., Wallach D., Kushtai G. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 51:1991;5602-5607.
2. Adolf G.R., Frühbeis B. Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity. Cytokine. 4:1992;180-184.
3. Asbury A.K., Arnason B.G.W., Adams R.D. The inflammatory lesion in idiopathic neuritis - Its role in pathogenesis. Medicine. 48:1969;173-215.
4. Asbury A.K., Arnasson B.G., Karp H.R., McFarlin D.E. Criteria for diagnosis of Guillain-Barré syndrome. Ann. Neurol. 3:1978;565-566.
5. Bansil S., Mithen F.A., Cook S.D., Sheffet A., Rohowsky-Kochan C. Clinical correlation with serum-soluble interleukin-2 receptor levels in Guillain-Barré syndrome. Neurology. 41:1991;1302-1305.
6. Beutler B., Milsark I.W., Cerami A. Cachectin/tumor necrosis factor: Production, distribution, and metabolic fate in vivo. J. Immunol. 135:1985;3972-3977.
7. Cottrell A.C., Mehta R.L. Cytokine kinetics in septic ARF patients on continuous veno-veno hemodialysis (CVVHD). J. Am. Soc. Nephrol. 3:1992;361.
8. Drapkin M.S., Wisch J.S., Gelfand J.A., Cannon J.G., Dinarello C.A. Plasmapheresis for fulminant meningococcemia. Ped. Infect. Dis. J. 8:1989;399-400.
9. Engelmann H., Aderka D., Rubinstein M., Rotman D., Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem. 264:1989;11974-11980.
10. Exley A.R., Smith N., Winer J.B. Tumour necrosis factor-α and other cytokines in Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry. 57:1994;1118-1120.
11. Gherardi R.K., Chouaïb S., Malapert D., Bélec L., Intrator L., Degos J.D. Early weight loss and high serum tumor necrosis factor-a levels in polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes syndrome. Ann. Neurol. 35:1994;501-505.
12. Girardin E., Roux-Lombard P., Grau G.E., Suter P., Gallati H., Dayer J.M. Imbalance between tumor necrosis factor α and soluble TNF receptor concentrations in severe meningococcemia. Immunology. 76:1992;20-23.
13. Griffin J.W., George R., Ho T. Macrophage systems in peripheral nerves. A review. J. Neuropathol. Exp. Neurol. 52:1993;553-560.
14. Hartung H.-P., Hughes R.A.C., Taylor W.A., Heininger K., Reiners K., Toyka K.V. T cell activation in Guillain-Barré syndrome and in MS: Elevated serum levels of soluble IL-2 receptors. Neurology. 40:1990;215-218.
15. Hartung H.-P., Reinerss K., Schmidt B., Stoll G., Toyka K.V. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuroapthy: Comparison with other neurological diseases of presumed immunopathogenesis. Ann. Neurol. 30:1991;48-53.
16. Iqbal A., Oger J.J.-F., Arnason B.G.W. Cell mediated immunity in idiopathic polyneuritis. Ann. Neurol. 9((Suppl.)):1981;65-69.
17. Jacobs C.A., Beckmann M.P., Mohler K., Maliszewski C.R., Fanslow W.C., Lynch D.H. Pharmacokinetic parameters and biodistribution of soluble cytokine receptors. Int. Rev. Exp. Pathol. 34B:1993;123-135.
18. Koski C.L., Gratz E., Sutherland J., Mayer R.F. Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barré syndrome. Ann. Neurol. 19:1986;573-577.
19. Langkopf F., Atzpodien J. Soluble tumour necrosis factor receptors as prognostic factors in cancer patients. Lancet. 344:1994;57-58.
20. Lantz M., Malik S., Slevin M.L., Olsson I. Infusion of tumor necrosis factor TNF causes an increase in circulating TNF-binding proteins in humans. Cytokine. 2:1990;402-406.
21. Maimone D., Annuziata P., Simone I.L., Livrea P., Guazzi G.C. Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J. Neuroimmunol. 47:1993;55-62.
22. Moldawer L.L. Interleukin-1, TNFα and their naturally occurring antagonists in sepsis. Blood Purif. 11:1993;128-133.
23. Molher K.M., Torrance D.S., Smith C.A., Goodwin R.G., Stremler K.E., Fung V.P., Madani H., Widmer M.B. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151:1993;1548-1561.
24. Olsson I., Lantz M., Nilsson E., Peetre C., Thysell H., Grubb A. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur. J. Haematol. 42:1989;270-275.
25. Pereira B.J., Shapiro L., King A.J., Falagas M.E., Strom J.A., Dinarello C.A. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 45:1994;890-896.
26. Redford E.J., Hall S.M., Smith K.J. Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain. 118:1995;869-878.
27. Rieckmann P., Martin S., Weichselbraun I., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Lüer W., Helwig A., Poser S. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology. 44:1994;2367-2372.
28. Saïd G., Hontebeyrie-Joskowicz M. Nerve lesions induced by macrophage activation. Res. Immunol. 143:1992;589-599.
29. Seckinger P., Dayer J.-M. Natural inhibitors of TNF. Immunol. Ser. 56:1992;217-236.
30. Seckinger P., Isaaz S., Dayer J.-M. Purification and biologic characterization of a specific tumor necrosis alpha inhibitor. J. Biol. Chem. 264:1989;11966-11973.
31. Selmaj K., Raine C.S. Tumor necrosis factor mediates myelin and oligodendrocytes damage in vitro. Ann. Neurol. 23:1988;339-346.
32. Selmaj K., Raine C.S., Cross A.H. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 30:1991;694-700.
33. Sharief M.K., McLean B., Thompson E.J. Elevated serum levels of tumor necrosis factor-α in Guillain-Barré syndrome. Ann. Neurol. 33:1993;591-596.
34. Spinas G.A., Keller U., Brockhaus M. Release of soluble receptor for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxemia. J. Clin. Invest. 90:1992;533-536.
35. Taylor W.A., Hughes R.A.C. T lymphocyte activation antigens in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J. Neurol. Sci. 24:1989;33-39.
36. Tsukada N., Miyagi K., Matsuda M., Yanagisawa N., Yone K. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J. Neurol. Sci. 102:1991;230-234.
37. Villard J., Roux-Lombard P., Hugli A., Dayer J.M. Could natural inhibitors of tumor necrosis factor-α modify the clinical course of fulminant meningococcemia. Crit. Care Med. 21:1993;1396-1400.
38. Ythier A., Gascon M.-P., Juillard P., Vesin C., Wallach D., Grau G.E. Protective effect of natural TNF-binding protein on human TNF-induced toxicity in mice. Cytokine. 5:1993;459-462.